Antidepressant pharmacotherapy: An update on current clinical and neurochemical perspectives

References

• FREELING P: Diagnosis and treatment of depression in general practice. Br. J. Psych iatry (1993) 163 (suppl. 20):14–19.
   Google Scholar
• HENRY JA: Debits and credits in the management of depression. Br. J. Psychiatry (1993) 163 (suppl. 20):33–39.
   Google Scholar
• ELIUN I, SHEAM T, WATKINS JT, IMBER SD, SOTSKY SM,COLLINS JF, GLASS DR, PILKONIS PA, LEBER WE, DO-CHERTY JP, FIESTER J, PARLOFF MB: National Institute Of Mental Health Treatment Of Depression Collaborative Research Programme; General Effectiveness Of Treat-ments. Arch. Gen. Psychiatry (1989) 46:971–983.
   PubMed Web of Science ®Google Scholar
• KLEIN DF, ROSS DC: Reanalysis of the National Institute Of Mental Health Treatment Of Depression Collabora-tive Research Programme General Effectiveness Report. Neuropsychopharmacology (1993) 8:241–251.
   PubMed Web of Science ®Google Scholar
• LADER M: Fluoxetine efficacy vs comparative drugs: An overview. Br. J. Psychiatry (1988) 153 (suppl. 3):51–58.
   Google Scholar
• LAPIERRE YD, BROWNE M, HORN E, OYEWUMI LK, SAR-ANTIDIS D, ROBERTS N, BADOE K, TESSIER: Treatment of major affective disorder with iluvoxamine. J. Clin. Psychiatry (1987) 48:65–68.
   PubMed Web of Science ®Google Scholar
• DECHANT KL, CLISSOLD SP: Paroxetine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depressive illness. Drugs (1991) 41:225–253.
   PubMed Web of Science ®Google Scholar
• POWER AC, COWEN PJ: Fluoxetine and suicidal behav-iour: Some clinical and theoretical aspects of a contro-versy. Br.J. Psychiatry (1992) 161:735–741.
   PubMed Web of Science ®Google Scholar
• An intelligent commentary on a vexed issue.
   Google Scholar
• BRYMER C, WINOGRAD CH: Fluoxetine in elderly pat-ients: Is there cause for concern? Journal of tbe American Geriatrics Society (1992) 40:902–905.
   PubMed Web of Science ®Google Scholar
• DUNNER DL, et al.: Two combined multicentre, double-blind studies of paroxetine and doxepin in geriatric patients. Journal of Clinical Psychiatry (1992) 53 (suppl. 2):57–60.
   Google Scholar
• DE WILDE J, et al.: A double-blind, comparative, mul-ticenter study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatrica Scandinavia (1993) 87:141–145.
   Google Scholar
• WAGNER W, PLEKKENPOL B, GRAY TE, VLASKAMP H, ESSERS H: Safety database on fluoxamine: Analysis and reports. Pharmacopsychiatry (1993) (suppl. 26):10–16.
   Google Scholar
• ANSSEAU M, et al.: A double-blind comparison of paroxetine and fluvoxamine in major depression. Euro-pean Neuropsychopharmacology (1993) 3:323–324.
   Google Scholar
• JAKOBSEN FM: Fluoxetine-induced sexual dysfunction and an open trail of yohimbine. Journal of Clinical Psychiatry 53:119–122.
   Google Scholar
• WILKINSON LO, DOURISH CT: Serotortin and animal behaviour. In: Serotonin receptor subtypes: Basic and clini-cal aspects. Wiley-Liss Inc. (1991) p147–210.
   Google Scholar
• A comprehensive review of the behavioural pharmacology of 5-HT ligands. Although these types of reviews are generally almost out of date as soon as they appear, its completeness means it will continue to be useful for some time to come.
   Google Scholar
• TEICHER MH, GLOD CL, COLE JO: Emergence of intense suicidal preoccupation during fluoxetine treatmentAnn. J. Psychiatry (1990) 147:207–210.
   Google Scholar
• FAVA M, ROSERBAUM JF: Suicidality and fluoxetine: Is there a relationship?J. din. Psychiatry (1991) 52:108–111.
   Google Scholar
• BEASLEY CM, DORNSEIF BE, BOSONWORTH JC, et al.. Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression. British J. of Psychiatry (1991) 303:685–692.
   Web of Science ®Google Scholar
• PITCHOT W, GONZALEZ-MORENO A, ANSSEAU M: Thera-peutic window for 5-HT reuptake inhibitors. Lancet (1992) 339:689.
   PubMed Web of Science ®Google Scholar
• BAKER GB, GREENSHAW AJ: Effects of long-term admini-stration of antidepressants and neuroleptics on recep-tors in the central nervous system. Gel. Mol. Neurobiol. (1989) 9:1–44.
   PubMed Web of Science ®Google Scholar
• BEL N, ARTIGAS F: Fluoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: An in vivo microdialysis study. Eur.J. Pharmacol. (1992) 229:101–103.
   PubMed Web of Science ®Google Scholar
• INVERNIZZI R, BELLI S, SAMANIN R: Citalopram's ability to increase the extracellular concentration of serotoninIn the dorsal raphe prevents the drug's effect in frontal cortex. Brain Res. (1992) 584:321–326.
   Google Scholar
• RU1IF,RJJ, AUERBACH SB: Acute uptake inhibition in- creases extracelleular serotonin in the rat forebrain. J. Pharmacol. Exp. Ther (1993) 265:1319–1324.
   PubMed Web of Science ®Google Scholar
• HRDINA PD, FOY B, HEPNER A, SUMMERS RJ: Antidepres- sant binding sites in brain: autoradiographic compari-son of [31]paroxethie and PIllimipramine localization and relationship to serotonin transporter. J. Pharmacol. Exp. Therap. (1990) 252:410–418.
   PubMed Web of Science ®Google Scholar
• CORTÉS R, SORIANO E, PAZOS A, PROBST A, PALACIOS 40JM: Autoradiography of antidepressant binding sites inthe human brain: Localization using [31I]imipramine and Plnparoxetine. Neuroscience (1988) 27:473–496.
   PubMed Web of Science ®Google Scholar
• ADELL A, ARTIGAS F: Differential effects of clomipram- ine given locally or systematically on extracellular5-hydroxytryptamine in raphe nuclei and frontal cor-tex. An in vivo microdialysis study. Naunyn-Schmiede-berg's Arch. Pharmacol. (1991) 343:237–244.
   PubMed Web of Science ®Google Scholar
• BEL N, ARTIGAS F: Chronic treatment with fluvoxamine increases extracefluIar serotonin in frontal cotrex but not in raphe nuclei. Synapse (1993) (in press).
   Google Scholar
• BLIER P, DE MONTIGNY C, CHAPUT Y: Modifications of the serotonin system by antidepressant treatments: Implications for the therapeutic response in major depressions. J. din. Psychopharmacol (1987) 7:24S–35S.
   Google Scholar
• Comprehensive review of electrophysiology of ADTs.
   Google Scholar
• NEWMAN ME, LERER B, SHAPIRA B: 5HT1A receptor-me- diated effects of antidepressants. Frog. Neuro-psycho-pharmacol. Biol. Psych. (1993) 17:1–19.
   PubMed Web of Science ®Google Scholar
• HENSLER JG, COVACHICH A, FRAZER A: A quantitative autoradiographk study of serotonin IA receptor regu-lation. Effect of 5,7-dihydroxytryptamine and antide-pressant treatments. Neuropsychopharmacology (1991) 4:131–144.
   Google Scholar
• ARTIGAS F, ADELL F, CORTÉS R, CELADA P: Increased extracelhdar concentrations of 5-HT in the raphe nu-cleus after uptake inhibition measured with in vivo dialysis: secondary effects on 5-HTiA receptors. Soc. Neurosci. Abs. (1991) 17:1488.
   Google Scholar
• ARTIGAS F: 5-HT and antidepressants: New views from microdialysis studies. TIPS (1993) 14:262.
   PubMed Web of Science ®Google Scholar
• ARTIGAS F, PEREZ V, ALVAREZ E: Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry (1994) (in press).
   Google Scholar
• HJORTH S: Serotonin 5HT lA autoreceptor blockade potentiates the ability of the 5HT reuptake inhibitor citalopram to increase nerve terminal output of 51ff in vivo: A microdialysis study. J. Neurochem. (1993) 60:776–779
   PubMed Web of Science ®Google Scholar
• CHAPUT Y, DE MONTIGNY C, SLIER P: Presynaptic and postsynaptic modifications of the serotonin system bylong-term administration of antidepressant treatments. Neuropsychopharmacology (1991) 5:219–229.
   PubMed Web of Science ®Google Scholar
• LAWRENCE AJ, MARSDEN CA: Terminal autoreceptor control of 5-hydroxytryptamine release as measured by in vivo microdialysis in the conscious guinea-pig. J. Neurochem. (1992) 58:142–146.
   PubMed Web of Science ®Google Scholar
• BLIER P: Modulation of 5HT neurotransmission by 5HT10 receptors: Possible therapeutic relevance. Euro-pean Neuropsychopharmacology (1993) 3:303–304.
   Google Scholar
• PINDAR RM, WIERINGA JH: Third generation antidepres- sants. Med. Res. Revs. (1993) 13:259–325.
   PubMedGoogle Scholar
• An authoritative review of the medicinal chemistry of the current candidates for future antidepressants.
   Google Scholar
• AMICO MF, ROBERTS DL, ROBENSON DS, SCHWIDESKI UE, COPP J: Placebo-controlled dose-ranging trial de-signs in phase 11 development of nefazodone. Psycho-pharmacol. Bull. (1990) 26:147–150.
   PubMed Web of Science ®Google Scholar
• GREENSHA'W AJ: Behavioural pharmacology of 5-HT3 receptor antagonists: A critical update on therapeuticpotential. TIPS 14:265–270.
   Google Scholar
• ANGEL I, SCHOCMAICER H, PROUTEAU M, GARREAU M, LANGER SZ: Litoxetine: A selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antic-metic properties. Eur. J. Pharmacol. (1993) 232:139–145.
   PubMed Web of Science ®Google Scholar
• CELADA P, ARTIGAS F: Monoamine oxidase inhibitors increase preferentially extracellular 5-hydroxytryp-tamine in the midbrain raphe nucleL A brain microdia-lysis study in the awake rat. Naunyn-Schmiedebetg's Arch. Pharmacol. (1993) 347:583–590.
   PubMed Web of Science ®Google Scholar
• CELADA P, BEL N, ARTIGAS F: The effects of brofaromine, a reversible MAO-A inhibitor, on extracellular sero-tonin in the raphe nuclei and frontal cortex of freely moving rat. J. Neural. Transm. (1994) (in press).
   Google Scholar
• BAKISH D, et al.: A comparison of moclobetnide, ami- triptyline and placebo in depression: A Canadian mul-ticenter study. Psychopharmacology (1992) 106:S98–102.
   Google Scholar
• BOUGEROL T, et al..: Efficacy and tolerability of mo-clobemide compared with fluvoxamine in depressive disorder (DSM HO. A French/Swiss double-blind trial Psychopharmacology (1992) 106:S102–105.
   Google Scholar
• REYNAERT C, PARENT M, MIREL J, JANNE P, HAAZEN L: Moclobemide versus fluoxetine for a major depressiveepisode. European Neuropsychopharmacology(1993) 3:329–330.
   Google Scholar
• DAKBOWSKA M, RYBALOWSKI JK: Moclobemide in treat-ment-resistant depression. European Neuropsychophar-macology (1993) 3:328–329.
   Google Scholar
• LAVIAN G, FINBERG JMP, YOUCLIM MBH: The advent of a new generation of monoamine oxidase inhibitor antidepressants: Pharmacologic studies with moclobe-mide and brofaromide. Clin. Neuropharmacology (1993) 16 (suppl. 2):51–57.
   Google Scholar
• WALDMELER PC, STöCKLIN K: The reversible MAO In-hibitor, brofaromine, inhibits serotonin uptake in vivo. Eur. J. Pharmacol. (1989) 169:197–204.
   PubMed Web of Science ®Google Scholar
• CELADA P, PEREZ J, ALVAREZ E, ARTIGAS F: Monoamine oxidase inhibitors phenelzine and brofaromine in-crease plasma serotonin and decrease 5-hydroxyindo-leacetic acid in patients with major depression: Relationship to clinical improvement J. Clin. Psycho-pharmacol. (1992) 12:309–315.
   PubMed Web of Science ®Google Scholar
• CHOU1NARD G, et al.: Brofaromine in depression: A Canadian multicenter placebo trial and a review of standard drug comparative studies. Clinical Neurophar-macology (1993) 16 (suppl. 2):S–51–554.
   Google Scholar
• WHITE HL, ASCHER JA: Preclinical and early clinical studies with BW 1370U87, a reversible competitive monoamine oxidase-A inhibitor. Clinical Neuropharma-col. (1993) 16 (supp1.2):S25–S33.
   Google Scholar
• MITCHELL PJ, FLETCHER A: Venlafaxine exhibits pre-?clinical antidepressant activity in the resident-intruder social interaction paradigm. Neuropharmacology (1993) 32:1001–1009.
   PubMed Web of Science ®Google Scholar
• MOYER JA, ANDREE TH, HASKINS JT, HUSBANDS GEM, MUTH EA: The pre-clinical pharmacological profile of venlaxafine: A novel antidepressant agent din. Neun9-pharmac. (1992) 15 (suppl. 1, pt B):435B.
   Google Scholar
• ECKMANN E, et al.: Rolipram in major depression: Res-ults of a double-blind comparative study with amItrip-tyline. Current Therapeutic Research (1988) 43:291–295.
   Google Scholar
• BROWN AS, GERSON S: Dopamine and depression. J. a•Neural. Transm. (Gen. Sect.) (1993) 91:75–109.
   PubMed Web of Science ®Google Scholar
• Exhaustive and thought-provoking review of a neglected topic in depression.
   Google Scholar